why choose us

First received: September 05, 2022

Clinical Trial: Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Study Status: Completed

Recruit Status: RECRUITING

Condition: Clinical Stage IV Cutaneous Melanoma AJCC v8

Study Type: INTERVENTIONAL


Official Title: A Phase I/II Study of Ex-Vivo Expanded Allogeneic Universal Donor (UD) TGFbi NK Cell Infusions in Combination With Temozolomide as a Lymphodepleting Agent in Patients With Melanoma Metastatic to

Brief Summary: This phase I/II trial tests the safety, side effects, and best dose of universal donor UD TGFbetai natural killer (NK) cells, and whether UD TGFbetai NK cells with temozolomide works to shrink tumors in patients with stage IV melanoma that has spread to the brain (metastatic to the brain).NK cells are immune cells that contribute to anti-tumor immunity by recognizing and destroying transformed or stressed cells.Temozolomide is in a class of medications called alkylating agents.It works by slowing or stopping…

Read more